Table 1 Baseline characteristics of participating patients matched for sex and age recruited from a HIV cohort between November 2015 and November 2016
|  | Total | HIV+ | HIV− | ||
|---|---|---|---|---|---|
CMV+ | CMV− | CMV+ | CMV− | ||
n | 92 | 23 | 23 | 23 | 23 |
Female, n (%) | 28 (30.4) | 7 (30.4) | 7 (30.4) | 7 (30.4) | 7 (30.4) |
Age (y), median (IQR) | 49.4 (44.3–54.3) | 50.1 (44.3–54.3) | 48.6 (44.3–54.0) | 49.4 (44.1–55.4) | 49.5 (45.2–55.0) |
Time since HIV infection (y), median (IQR) | 14.5 (6.6–21.0) | 12.5 (6.6–19.7) | 17.1 (6.5–23.1) | NA | NA |
CD4 nadir (cells/µl), median (IQR) | 190.5 (95.0–255.0) | 197.0 (95.0–257.0) | 173.5 (95.0–223.0) | NA | NA |
VL < LoD (months), median (IQR) | 63.0 (20.0–99.0) | 64.0 (20.0–96.0) | 62.0 (15.0–108.0) | NA | NA |
CD4, (cells/µl), median (IQR) | NA | 469.5 (364.5–635.3) | 564.0 (380.8–727.3) | 825.0 (584.8–1054.0) | 758.0 (593.0–1045.0) |